Efficacy, safety, and quality-of-life of treatments for acute relapses of multiple sclerosis: results from a literature review of randomized controlled trials

References

• Trapp BD, Nave KA. Multiple sclerosis: an immune or neurodegenerative disorder? Annu Rev Neurosci. 2008;31:247–269. doi:10.1146/annurev.neuro.30.051606.09431318558855
   PubMed Web of Science ®Google Scholar
• Filippini G, Brusaferri F, Sibley WA, et al. Corticosteroids or ACTH for acute exacerbations in multiple sclerosis. Cochrane Database Syst Rev. 2000;(4):CD001331.11034713
   PubMedGoogle Scholar
• Lublin FD, Baier M, Cutter G. Effect of relapses on development of residual deficit in multiple sclerosis. Neurology. 2003;61(11):1528–1532. doi:10.1212/01.wnl.0000096175.39831.2114663037
   PubMed Web of Science ®Google Scholar
• Bernard JT. Treating Acute Relapses in MS. CME released MedScape; 3 17, 2015 Available from: https://www.medscape.org/viewarticle/839227. Accessed June 14, 2019.
   Google Scholar
• Food and Drug Administration. SOLU-MEDROL® (Methylprednisolone Sodium Succinate for Injection, USP).  FDA; 2011 Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/011856s103s104lbl.pdf. Accessed June 14, 2019.
   Google Scholar
• Acthar prescribing information. H. P. Acthar Gel for Intramuscular/Subcutaneous Use. Mallinckrodt Pharmaceuticals; 1 2015 Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022432s000lbl.pdf. Accessed June 14, 2019.
   Google Scholar
• Cortese I, Chaudhry V, So YT, Cantor F, Cornblath DR, Rae-Grant A. Evidence-based guideline update: plasmapheresis in neurologic disorders: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2011;76(3):294–300. doi:10.1212/WNL.0b013e318207b1f621242498
   PubMed Web of Science ®Google Scholar
• Schwartz J, Padmanabhan A, Aqui N, et al. Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the Writing Committee of the American Society for Apheresis: the seventh special issue. J Clin Apher. 2016;31(3):149–162. doi:10.1002/jca.2147027322218
   PubMed Web of Science ®Google Scholar
• Scheinfeld N. Intravenous Immunoglobulin. Medscape; 2016.
   Google Scholar
• Food and Drug Administration. Immune Globulin Intravenous (IGIV) Indications. FDA; 2018.
   Google Scholar
• Nickerson M, Marrie RA. The multiple sclerosis relapse experience: patient-reported outcomes from the North American Research Committee on Multiple Sclerosis (NARCOMS) Registry. BMC Neurol. 2013;13:119. doi:10.1186/1471-2377-13-20224016260
   PubMed Web of Science ®Google Scholar
• Stoppe M, Busch M, Krizek L, Then Bergh F. Outcome of MS relapses in the era of disease-modifying therapy. BMC Neurol. 2017;17(1):151. doi:10.1186/s12883-017-0927-x28784102
   PubMed Web of Science ®Google Scholar
• Berkovich R. Treatment of acute relapses in multiple sclerosis. Neurotherapeutics. 2013;10(1):97–105. doi:10.1007/s13311-012-0160-723229226
   PubMed Web of Science ®Google Scholar
• National Multiple Sclerosis Society. Relapse Management. National Multiple Sclerosis Society; 2009.
   Google Scholar
• National Multiple Sclerosis Society. Recommendations regarding Corticosteroids in the Management of Multiple Sclerosis. National Multiple Sclerosis Society; 2008.
   Google Scholar
• Goodin DS, Frohman EM, Garmany GP Jr., et al. Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology. 2002;58(2):169–178. doi:10.1212/wnl.58.2.16911805241
   PubMed Web of Science ®Google Scholar
• Hogg RV, Tanis EA, Zimmerman DL. Probability and Statistical Inference. Ninth ed. Boston: Pearson Education, Inc.; 2014.
   Google Scholar
• NICE. Single Technology Appraisal: User Guide for Company Evidence Submission Template. London: National Institute for Health and Care Excellence; 2015.
   Google Scholar
• NICE. Single Technology Appraisal. London: National Institute for Health and Care Excellence; 2012.
   Google Scholar
• Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983;33(11):1444–1452. doi:10.1212/wnl.33.11.14446685237
   PubMed Web of Science ®Google Scholar
• U.S. Department of Veterans Affairs. Kurtzke Expanded Disability Status Scale. 2018.
   Google Scholar
• Collins CDE, Ivry B, Bowen JD, et al. A comparative analysis of patient-reported expanded disability status scale tools. Mult Scler. 2016;22(10):1349–1358. doi:10.1177/135245851561620526564998
   PubMed Web of Science ®Google Scholar
• Milligan NM, Newcombe R, Compston DA. A double-blind controlled trial of high dose methylprednisolone in patients with multiple sclerosis: 1. Clinical effects. J Neurol Neurosurg Psychiatry. 1987;50(5):511–516. doi:10.1136/jnnp.50.5.5113295122
   PubMed Web of Science ®Google Scholar
• Durelli L, Baggio GF, Bergamasco B, et al. Early immunosuppressive effect of parenteral methylprednisolone in the treatment of multiple sclerosis. Acta Neurol (Napoli). 1985;7(3–4):338–344.3904340
   PubMedGoogle Scholar
• Durelli L, Cocito D, Riccio A, et al. High-dose intravenous methylprednisolone in the treatment of multiple sclerosis: clinical-immunologic correlations. Neurology. 1986;36(2):238–243. doi:10.1212/wnl.36.2.2383511404
   PubMed Web of Science ®Google Scholar
• Filipovic SR, Drulovic J, Stojsavljevic N, Levic Z. The effects of high-dose intravenous methylprednisolone on event-related potentials in patients with multiple sclerosis. J Neurol Sci. 1997;152(2):147–153.9415535
   PubMed Web of Science ®Google Scholar
• Fierro B, Salemi G, Brighina F, et al. A transcranial magnetic stimulation study evaluating methylprednisolone treatment in multiple sclerosis. Acta Neurol Scand. 2002;105(3):152–157.11886356
   PubMed Web of Science ®Google Scholar
• Oliveri RL, Valentino P, Russo C, et al. Randomized trial comparing two different high doses of methylprednisolone in MS: a clinical and MRI study. Neurology. 1998;50(6):1833–1836. doi:10.1212/wnl.50.6.18339633736
   PubMed Web of Science ®Google Scholar
• La Mantia L, Eoli M, Milanese C, Salmaggi A, Dufour A, Torri V. Double-blind trial of dexamethasone versus methylprednisolone in multiple sclerosis acute relapses. Eur Neurol. 1994;34(4):199–203. doi:10.1159/0001170387915989
   PubMed Web of Science ®Google Scholar
• La Mantia L, Milanese C, Salmaggi A, Eoli M, Ciusani E, Nespolo A. Double blind randomized trial of dexamethasone high dose methylprednisolone and low dose methylprednisolone in multiple sclerosis bouts.J Neurology 1990;237(Suppl 1):S20.
   Google Scholar
• Chataway J, Porter B, Riazi A, et al. Home versus outpatient administration of intravenous steroids for multiple-sclerosis relapses: a randomised controlled trial. Lancet Neurol. 2006;5(7):565–571. doi:10.1016/S1474-4422(06)70450-116781986
   PubMed Web of Science ®Google Scholar
• Glass-Marmor L, Paperna T, Ben-Yosef Y, Miller A. Chronotherapy using corticosteroids for multiple sclerosis relapses. J Neurol Neurosurg Psychiatry. 2007;78(8):886–888. doi:10.1136/jnnp.2006.10400017056624
   PubMed Web of Science ®Google Scholar
• Schmitt E, Behm E, Buddenhagen F, et al. Immunoadsorption (IA) versus plasma exchange (PE) in multiple sclerosis—first results of a double blind controlled trial. Prog Clin Biol Res. 1990;337:289–292.2191322
   PubMedGoogle Scholar
• Ramo-Tello C, Grau-Lopez L, Tintore M, et al. A randomized clinical trial of oral versus intravenous methylprednisolone for relapse of MS. Mult Scler. 2014;20(6):717–725. doi:10.1177/135245851350883524144876
   PubMed Web of Science ®Google Scholar
• Martinelli V, Rocca MA, Annovazzi P, et al. A short-term randomized MRI study of high-dose oral vs intravenous methylprednisolone in MS. Neurology. 2009;73(22):1842–1848. doi:10.1212/WNL.0b013e3181c3fd5b19949030
   PubMed Web of Science ®Google Scholar
• Le Page E, Veillard D, Laplaud DA, et al. Oral versus intravenous high-dose methylprednisolone for treatment of relapses in patients with multiple sclerosis (COPOUSEP): a randomised, controlled, double-blind, non-inferiority trial. Lancet. 2015;386(9997):974–981. doi:10.1016/S0140-6736(15)61137-026135706
   PubMed Web of Science ®Google Scholar
• Barnes D, Hughes RA, Morris RW, et al. Randomised trial of oral and intravenous methylprednisolone in acute relapses of multiple sclerosis. Lancet. 1997;349(9056):902–906.9093250
   PubMed Web of Science ®Google Scholar
• Alam S, Kyriakides T, Lawden M, Newman P. Methylprednisolone in multiple sclerosis: a comparison of oral with intravenous therapy at equivalent high dose. J Neurol Neurosurg Psychiatry. 1993;56(11):1219–1220. doi:10.1136/jnnp.56.11.12198229035
   PubMed Web of Science ®Google Scholar
• Grau-Lopez L, Tintore M, Ramio-Torrenta L, et al. Relationship between relapses and quality of life in patients with relapsing remitting multiple sclerosis. Mult Scler J. 2014;20:420.
   Google Scholar
• Najmi Varzaneh F, Najmi Varzaneh F, Azimi AR, Rezaei N, Sahraian MA. Efficacy of combination therapy with erythropoietin and methylprednisolone in clinical recovery of severe relapse in multiple sclerosis. Acta Neurol Belg. 2014;114(4):273–278. doi:10.1007/s13760-014-0286-y24604685
   PubMed Web of Science ®Google Scholar
• Sorensen PS, Haas J, Sellebjerg F, Olsson T, Ravnborg M, Group TS. IV immunoglobulins as add-on treatment to methylprednisolone for acute relapses in MS. Neurology. 2004;63(11):2028–2033. doi:10.1212/01.wnl.0000145798.61383.3915596745
   PubMed Web of Science ®Google Scholar
• Visser LH, Beekman R, Tijssen CC, et al. A randomized, double-blind, placebo-controlled pilot study of i.v. immune globulins in combination with i.v. methylprednisolone in the treatment of relapses in patients with MS. Mult Scler. 2004;10(1):89–91. doi:10.1191/1352458504ms978sr14760960
   PubMed Web of Science ®Google Scholar
• Weiner HL, Dau PC, Khatri BO, et al. Double-blind study of true vs. sham plasma exchange in patients treated with immunosuppression for acute attacks of multiple sclerosis. Neurology. 1989;39(9):1143–1149. doi:10.1212/wnl.39.9.11432549450
   PubMed Web of Science ®Google Scholar
• Weiner HL, Dau PC, Khatri BO, et al. Double-blind study of true vs. sham plasmapheresis in patients being treated with immunosuppression for acute attacks of multiple sclerosis. Prog Clin Biol Res. 1990;337:283.2162062
   PubMedGoogle Scholar
• Henderson WG, Tourtellotte WW, Potvin AR, Rose AS. Methodology for analyzing clinical neurological data: ACTH in multiple sclerosis. Clin Pharmacol Ther. 1978;24(2):146–153. doi:10.1002/cpt1978242146209928
   PubMed Web of Science ®Google Scholar
• Rose AS, Kuzma JW, Kurtzke JF, Sibley WA, Tourtellotte WW. Cooperative study in the evaluation of therapy in multiple sclerosis: ACTH vs placebo in acute exacerbation. Trans Am Neurol Assoc. 1969;94:126–133.4313957
   PubMedGoogle Scholar
• Rose AS, Kuzma JW, Kurtzke JF, Namerow NS, Sibley WA, Tourtellotte WW. Cooperative study in the evaluation of therapy in multiple sclerosis. ACTH vs. placebo—final report. Neurology. 1970;20(5):1–59. doi:10.1212/wnl.20.5_part_2.1
   PubMed Web of Science ®Google Scholar
• Simsarian JP, Saunders C, Smith DM. Five-day regimen of intramuscular or subcutaneous self-administered adrenocorticotropic hormone gel for acute exacerbations of multiple sclerosis: a prospective, randomized, open-label pilot trial. Drug Des Devel Ther. 2011;5:381–389. doi:10.2147/DDDT.S19331
   PubMed Web of Science ®Google Scholar
• Craig J, Young CA, Ennis M, Baker G, Boggild M. A randomised controlled trial comparing rehabilitation against standard therapy in multiple sclerosis patients receiving intravenous steroid treatment. J Neurol Neurosurg Psychiatry. 2003;74(9):1225–1230. doi:10.1136/jnnp.74.9.122512933923
   PubMed Web of Science ®Google Scholar
• Meyer-Moock S, Feng YS, Maeurer M, Dippel FW, Kohlmann T. Systematic literature review and validity evaluation of the Expanded Disability Status Scale (EDSS) and the Multiple Sclerosis Functional Composite (MSFC) in patients with multiple sclerosis. BMC Neurol. 2014;14:58. doi:10.1186/s12883-014-0196-x24666846
   PubMed Web of Science ®Google Scholar
• Sharrack B, Hughes RA, Morris RW, et al. The effect of oral and intravenous methylprednisolone treatment on subsequent relapse rate in multiple sclerosis. J Neurol Sci. 2000;173(1):73–77.10675582
   PubMed Web of Science ®Google Scholar
• Lal R, Bell S, Challenger R, et al. Pharmacodynamics and tolerability of repository corticotropin injection in healthy human subjects: a comparison with intravenous methylprednisolone. J Clin Pharmacol. 2016;56(2):195–202. doi:10.1002/jcph.58226120075
   PubMed Web of Science ®Google Scholar
• Benko A, Mcaloose C, Becker P, et al. Repository corticotrophin injection exerts direct acute effects on human B cell gene expression distinct from the actions of glucocorticoids. Clin Exp Immunol. 2018;192(1):68–81. doi: 10.1111/cei.13089.
   Web of Science ®Google Scholar
• Due B, Becker P, Coyle P. A prospective observational registry of repository corticotropin injection for the treatment of multiple sclerosis relapse: baseline characteristics and interim results. CMSC. 2017.
   Google Scholar
• Perrin Ross A, Williamson A, Smrtka J, et al. Assessing relapse in multiple sclerosis questionnaire: results of a pilot study Mult Scler Int. 2013:1–8.
   Google Scholar